Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488380 | 0.91 | RAF1 (0.44) | SMN1; SMN2MTNR1BMMP13KDM4EPOLB | |
| SCHEMBL20957057 | 0.91 | HSD17B10 (0.46) | ALDH1A1HPGD | |
| SCHEMBL3489383 | 0.89 | ALDH1A1 (0.42) | SMN1; SMN2MTNR1BMMP13KDM4EPOLB | |
| SCHEMBL3487214 | 0.88 | ALDH1A1 (0.54) | SMN1; SMN2POLBALDH1A1MEN1KMT2A | |
| SCHEMBL3488407 | 0.86 | EGLN1 (0.39) | SMN1; SMN2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL3487570 | 0.85 | MMP13 (0.42) | SMN1; SMN2MMP13KDM4EPOLBUSP2 | |
| SCHEMBL3487598 | 0.85 | HTR2A (0.44) | PGR | |
| SCHEMBL3488473 | 0.84 | MAPK14 (0.51) | — | |
| SCHEMBL3488176 | 0.84 | TEAD4 (0.46) | SMN1; SMN2MMP13POLBALDH1A1 | |
| SCHEMBL3488035 | 0.84 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2138484-B1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2138484-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | PPARG, GPR119, PPARA | SMN1; SMN2 4397/4885MTNR1B 344/4885MTNR1A 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.